Access
To read this story in full you will need to login or make a payment (see right).
Article
Nature 449, 557-563 (4 October 2007) | doi:10.1038/nature06188; Received 13 April 2007; Accepted 14 August 2007
Open Innovation Challenges
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
-
Optimizing Sub-cellular Localization Tags
The Seeker is looking for methods to optimize sub-cellular localization tags for protein expression....
nature jobs
Academic Anatomic Pathologist
- Mayo Clinic
- Scottsdale, Arizona, USA
Sr. Scientific Manager / Chief Scientific Manager- Discovery Metabolism and Pharmacokinetics (MAP)
- Syngene International
- Bangalore, Karnataka 560099 India
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Antoine E. Karnoub1, Ajeeta B. Dash2, Annie P. Vo1, Andrew Sullivan2, Mary W. Brooks1, George W. Bell1, Andrea L. Richardson3, Kornelia Polyak4, Ross Tubo2 & Robert A. Weinberg1
- Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA
- Genzyme Corporation, Framingham, Massachusetts 01701, USA
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
Correspondence to: Robert A. Weinberg1 Correspondence and requests for materials should be addressed to R.A.W. (Email: weinberg@wi.mit.edu).
Abstract
Mesenchymal stem cells have been recently described to localize to breast carcinomas, where they integrate into the tumour-associated stroma. However, the involvement of mesenchymal stem cells (or their derivatives) in tumour pathophysiology has not been addressed. Here, we demonstrate that bone-marrow-derived human mesenchymal stem cells, when mixed with otherwise weakly metastatic human breast carcinoma cells, cause the cancer cells to increase their metastatic potency greatly when this cell mixture is introduced into a subcutaneous site and allowed to form a tumour xenograft. The breast cancer cells stimulate de novo secretion of the chemokine CCL5 (also called RANTES) from mesenchymal stem cells, which then acts in a paracrine fashion on the cancer cells to enhance their motility, invasion and metastasis. This enhanced metastatic ability is reversible and is dependent on CCL5 signalling through the chemokine receptor CCR5. Collectively, these data demonstrate that the tumour microenvironment facilitates metastatic spread by eliciting reversible changes in the phenotype of cancer cells.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Evidence that bone morphogenetic protein 4 has multiple biological functions during kidney and urinary tract developmentKidney International Original Article
Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cellsOncogene Original Article
See all 53 matches for Research
